Organization
Shandong Academy of Medical Sciences
4 abstracts
Abstract
Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study.Org: Shandong Academy of Medical Sciences,
Abstract
Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.Org: Fudan University Shanghai Cancer Center, Phase I Cinical Trial Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China, Jinan Central Hospital, Shandong University, Shandong University of Traditional Chinese Medicine Affiliated Hospital,
Abstract
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.Org: Department of Gastroenterological Surgery II, Hokkaido University, Faculty of Medicine, Sapporo, Japan, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China,
Abstract
Nomograms for predicting survival in patients with HER2 negative breast cancer.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University, Shandong Academy of Medical Sciences,